SENNEN POTASH CORPORATION

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES

December 3, 2018 **SN.V: TSX Venture Exchange**

Sennen Enters into Share Exchange Agreement to Acquire Licensed Producer under the *Cannabis Act*

VANCOUVER, BC: Sennen Potash Corporation ("Sennen" or the "Company") announces the signing of a binding share exchange agreement ("Share Exchange Agreement") dated November 19, 2018, whereby Sennen will acquire all of the issued and outstanding common shares of privately-held Folium Life Sciences Inc. ("Folium") in an all-share transaction (the "Transaction"). Folium is a privately held licensed producer as defined under the *Cannabis Act* (Canada).

Terms of the Transaction

Under the provisions of the Transaction, Sennen will acquire all of the issued and outstanding securities of Folium (the "Folium Securities") in consideration of the issuance of 93,700,000 common shares of the Company at a deemed price of $0.40 per share and Folium will become a wholly owned subsidiary of Sennen. The Transaction is an arm's length transaction. A finder's fee of 6,000,000 common shares is expected to be paid in connection with the Transaction to an arm's length party.

In connection with the Transaction, Sennen anticipates it will delist its common shares from the TSX Venture Exchange ("TSXV") and list the common shares on the Canadian Securities Exchange ("CSE") such that on the Closing Date, the common shares of Sennen would be listed on the CSE.

Additionally, at closing of the Transaction, all of the current directors and officers of Sennen would resign in favor of nominees selected by Folium, being Fonda Betts, who will be appointed as Executive Chairman and Chad Clelland, who will also be appointed as President and Chief Executive Officer as well as three other additional nominees. Additional details concerning the remaining proposed board and management will be provided in a further press release regarding the Transaction.

Fonda Betts, Executive Chairman

Fonda Betts has extensive executive management experience and knowledge of the cannabis industry. Ms. Betts co-founded and served as Chief Executive Officer and a director of several successful businesses including a chain of west coast retail hydroponic stores, and a national wholesale garden supply and fertilizer manufacturing company.

In addition, Ms. Betts co-founded the Greenleaf Medical Clinic in 2011 with a focus on providing Canadians with access to information about the medical cannabis industry. For the past 10 years, Ms. Betts has been focused on leading and managing the Greenleaf Medical Clinic and

MedicalMarijuana.ca, a Canadian website focused on providing cannabis solutions, to provide Canadians with reliable resources and quality services. Ms. Betts was ranked in as one of Canada's Top 20 Woman Entrepreneurs in "Profit" Magazine.

Chad Clelland, President and Chief Executive Officer

Chad Clelland co-founded the Greenleaf Medical Clinic in 2011 and MedicalMarijuana.ca in 2009 with Fonda Betts. For the past three years, Mr. Clelland has served as management for both companies and is recognized as a leader in the cannabis industry.

Mr. Clelland brings considerable management and expertise to Folium. He successfully designed and implemented Folium's production facility on Vancouver Island. Additionally, Mr. Clelland has extensive expertise in cannabis production, GMPs, genetics, quality control, and managing user and patient expectations.

About Folium

Folium is a privately-held company and holds a license to produce cannabis under the *Cannabis Act* (Canada).

On June 22, 2018 Folium was granted a cultivation license by Health Canada for its indoor facility located on Vancouver Island. Through evidence-based research, observation of patient experiences and clinic researched data points, Folium aims to deliver its high quality, consistent, and proprietary cannabis options to its users through Folium's GMP production facility.

Financing

The Company intends to complete a non-brokered private placement offering of up to 7,500,000 subscription receipts (the "Subscription Receipts") at a price of $0.40 per Subscription Receipt. The Subscription Receipts would entitle the holder thereof to receive (without any further action or payment of any additional consideration) one unit ultimately of the Resulting Issuer (a "Unit"). Each Unit will consist of one common share and one-half of one common share purchase warrant. Each full warrant will entitle the holder to purchase an additional common share at the price of $0.80 per share for a period of 24 months from the closing of the Transaction.

The net proceeds from the Financing will be used for the development of the Company's proposed business following its acquisition of Folium and for general working capital purposes

Conditions of the Transaction

The closing of the Transaction is subject to a number of conditions, including: (i) completion of due diligence by Sennen (ii) the completion of the Financing; (iii) receipt of all applicable regulatory approvals for the transaction including the approval of the CSE or the TSXV, as may be determined, for the listing of the Sennen common shares and, if applicable, of the TSXV for the delisting of the Sennen common shares; (iv) Folium's license to produce shall not have been revoked or otherwise terminated; (v) no material adverse change shall have occurred in Folium or Sennen; and (vi) other customary conditions for a transaction of this nature.

Additional Information

Further details concerning the Transaction, Folium and the Financing, as well as other matters, will be announced and incorporated into a listing statement concerning the Transaction. Trading in the common shares of the Company is expected to remain halted pending completion of the Transaction. There can be no assurance that trading in the common shares of the Company will resume prior to completion of the Transaction.

Following the completion of the Transaction, Sennen expects to change its name to a name to be determined by the parties. A new trading symbol would also be assigned.

Sennen Potash Corporation

Brent Hahn – CEO & Director
(604) 641-8993

Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS

Not for distribution to United States wire services or dissemination in the United States. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Statements about the closing of the Transaction, expected terms of the Transaction, the number of securities of the Company that may be issued in connection with the Transaction, the ownership of the Company, the terms of and the completion of the Financing, and the parties’ ability to satisfy any and all other closing conditions, and receive necessary regulatory and stock exchange approvals in connection therewith, are all forward-looking information.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include failure to obtain regulatory approval, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Transaction will occur or that, if the Transaction does occur, it will be completed on the terms described above. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.

Completion of the Transaction is subject to a number of conditions, including stock exchange acceptance and, if applicable, disinterested Shareholder approval. Where applicable, the Transaction cannot close until the required Shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the Listing Statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Sennen should be considered highly speculative. The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.